Broad Pattern Project

Do you have an upcoming surgery or biopsy?

Are you interested in donating fresh tumor tissue?

FCF has an exciting new partnership with the Broad Institute of MIT & Harvard and Pattern.org (an initiative of the Rare Cancer Research Foundation) which allows patients to donate excess fresh tumor tissue from surgery or biopsy to research.  We’re working with these partners to create new rare cancer cell lines through the Broad’s “Cancer Cell Line Project” (CCLP).  Only a limited number of indications are initially included in this project and fibrolamellar is included so we’re letting patients with upcoming resections or biopsies know about this exciting opportunity.

 

Here’s how it works:

  • Go to https://www.pattern.org/index#first-section
  • Click on “join us” to view more information about the project.
  • You’ll be asked to answer a few basic questions (i.e. name, phone number and   diagnosis)
  • Then you’ll be able to access details about the project.
  • If you decide it’s right for you, you can sign an online consent to donate your excess tissue.

 

That’s all you have to do as Pattern will work directly with your doctor, as well as the local pathologist to coordinate the contribution.

Only excess fresh tissue not needed for your clinical care will be taken.

Pattern.org will de-identify the tissue sample (which means they’ll remove all personal information) and have the sample transported directly to the Broad Institute for processing.

There is NO cost to you.

You’ll be notified once your tissue sample has been received at the Broad, but won’t receive any other information back from the project.

The great news is that if a successful cell line model is created from a tissue sample, it will be genetically characterized and the cell line and corresponding de-identified data will be placed in the public domain providing access to qualified researchers throughout the world for use in their research.  By doing so, this will provide an invaluable resource for researchers to better understand fibrolamellar and hopefully lead to science that contributes to the development of more effective treatments.